HomeTeam

Team of world-class scientists and highly experienced entrepreneurs and business leader

Our scientific team consists of  the leading global authorities on CA IX, including co-discoverers of CA IX, who have a combined joint expertise of more than 80 years on this topic.

Groundbreaking research on hypoxia has been a part of the subject for which the 2019 Nobel Prize for Medicine has been awarded; -three of our team members have co-authored recent studies on hypoxia and CA IX with one of its laureates, Sir. Peter J. Ratcliffe and still continue collaborating with him.

EXECUTIVE BOARD

Jaromir Pastorek
Jaromir Pastorek
Founder, Chief Scientific Officer and Chairman of the Scientific Board

Professor Jaromír Pastorek is an excellent Slovak biochemist, pedagogue, and discoverer of the gene encoding a protein CA IX which serves as an endogenous marker of hypoxia in tumors. At present, prof. Pastorek is a Principal Investigator at the Biomedical Research Center of Slovak Academy of Sciences (BMC SAS). Prof. Pastorek was the President of Slovak Academy of Sciences from 2009 until 2015. Formerly he also served as the Plenipotentiary of the Slovak Government for Research and Innovation.

Jaromír Pastorek is a Member of the Board of the Slovak Society for Biochemistry and Molecular Biology from 1998. He is the Member of the European Cancer Research Association (EACR), the Member of the Commission for the PhD degree in Molecular biology and Virology, the Elected member of the European Academy of Sciences and Arts (2008), and member of several others international scientific committees and organizations. He is the coinventor on US patent “MN Gene and Protein” (Zavada, Pastorekova, Pastorek) No. 5,384,676 issued in 1995 and on further 50 patents related to different aspect of MN protein (now named CA IX).

Prof. Pastorek’s research activities are focused on the identification and research of cancer diagnostic and therapeutic targets. His main scientific interest is the analysis of molecular mechanisms of adaptive response to hypoxia and acidosis during tumor development. He is a Principal Investigator of several research projects related to clinical use of CA IX. Prof. Pastorek has published over 185 papers, books, book chapters, and reviews.

ADVISORY BOARD

Adrian Harris
Adrian Harris

Cancer Research UK Professor of Medical Oncology at Oxford University, Editor-in-Chief of the British Journal of Cancer, Director of Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine, Chairman of the CRUK Oxford Cancer Centre, joint lead of the Cancer theme of the Comprehensive Biomedical Research Centre in Oxford, fellow of the Academy of Medical Sciences

Philippe Lambin
Philippe Lambin

Head of the „disease agnostic“ Department of Precision Medicine at Maastricht University, Netherlands. He is a clinician, radiation oncologist, molecular biologist and pioneer in translational research with a focus on tumour  hypoxia, radiomics, living medicine and decision support systems. He is an “ERC advanced & ERC PoC (2x) grant laureate” from 2016, 2018 & 2020 and a co-author of more than 540 peer reviewed scientific papers. Prof. Lambin has extensive experience with clinical trials. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research“ organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials.

Margaret Ashcroft
Margaret Ashcroft

Professor at the Department of Medicine at Cambridge University, Fellow of the Royal Society of Biology and Honorary Member of the Royal College of Radiologists

Silvia Pastorekova
Silvia Pastorekova

Professor Silvia Pastoreková is an excellent Slovak virologist, scientist and pedagogue. Since 2016, she serves as a Director of the Biomedical Research Centre of Slovak Academy of Sciences (BMC SAS) and Head of the Department of Tumor Biology at the Institute of Virology BMC SAS. She is the coinventor on US patent “MN Gene and Protein” (Zavada, Pastorekova, Pastorek) No. 5,384,676 issued in 1995 and on further 50 patents related to different aspect of MN protein (now named CA IX).

She was awarded with several prizes, e.g. the Crystal Wing in category Medicine and Science in 2005, the Slovak Woman of the Year 2009, and The Academia of Education Award in 2010 for her contribution to science, education and popularization. As principal investigator, she participated in two project – the EU’s 6th and 7th Framework Programme (EUROXY and METOXIA), two Marie Curie training networks (CELLCHECK and EngCaBra) and several additional national and international projects. Since 2004, prof. Pastoreková is a Member of the Pathobiology Group of the European Organisation for Research and Treatment of Cancer (EORTC). Since 2006, she is a Representative of the Slovak Republic in the inter-governmental organization The European Molecular Biological Conference (EMBC). In 2017, she was nominated as chairwoman of the International Society for Cancer Metabolism (ISCaM).

Her research work focuses on the role of tumor microenvironment in cancer progression through study the mechanisms of tumor cell adaptation to hypoxia and acidosis. Prof. Pastoreková has published over 190 papers, books, book chapters, and reviews.

SCIENTIFIC TEAM

Dr. Ingeborg Režuchová
Dr. Ingeborg Režuchová

Ingeborg Režuchová is a Senior Scientist at the Biomedical Research Center, Slovak Academy of Sciences. She is biomedical scientist with over 25 years of experience conducting research in molecular biology, virology and immunology.  Her current scientific interest is the analysis of molecular mechanisms of adaptive response to hypoxia and acidosis during tumor development with an emphasis on the identification and research of cancer biomarkers and therapeutic targets.

She graduated from Comenius University, Faculty of Natural Sciences with a degree in Virology (1995). In 2000 she obtained the PhD degree at the Faculty of Natural Sciences, Comenius University Bratislava.

She worked as Postdoctoral Associate at the Department of Viral Genetics, Institute of Applied Virology, German Cancer Research Centre in Heidelberg, Germany, in 2001.

Dr. Režuchová is co-founder of MABPRO, a.s. and also co-author of a company’s research and development strategy. She participates in building of diagnostic portfolio of company – she is responsible for the development and clinical evaluation of company’s diagnostic products.

Dr. Martina Labudová
Dr. Martina Labudová

Dr. Martina Labudova finished her degree at Comenius University in Bratislava, Slovakia in Virology specialisation. She was awarded by the president of Slovak republic as a best young scientist (2010) and received a Schwarz fund award. In 2007 she had worked in the laboratory of Dr. Bradley Wouters, PhD and Dr. Phillip Lambin, PhD at the Maastricht University, Netherlands specialised on the hypoxia and radiology. She was also attending the laboratory of Dr. Juraj Petrik PhD at the Scotish national blood transfusion service in Edinburgh. Her research in the field of virology was focused on the transmission of viral particles during persistent infection of LCMV, while in the field of oncology, she studies the effects of oxygen on the radiotherapy.

Dr. Labudova works also as the editor of the virology journal Acta Virologica.

Dr. Miriam Zaťovičová
Dr. Miriam Zaťovičová

Miriam Zaťovičová is a Slovak biochemist and scientist. At present, she is a Senior Scientist at the Biomedical Research Center of Slovak Academy of Sciences, Department of Tumor Biology. She is the coinventor on US patents: US 07846673, US 07833728, US 07816493 „Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX’S coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes“. She graduated from the Department of Biochemistry
Faculty of Natural Sciences, Comenius University in Bratislava
, in 1983 (RNDr.) and obtained her PhD-degree in 1992. Between 1991 – 1992 she worked as a visiting researcher in the laboratory of Professor Abraham Karpas at University of Cambridge, MRC centre, United Kingdom.

Her main scientific interest focuses on the role of CA IX and its extracellular forms in tumor biology and immunology. Her research activities are focused on the production and characterization of monoclonal antibodies specific to CA IX and its therapeutic potential.

Dr. Monika Baráthová
Dr. Monika Baráthová

Monika Baráthová is a Senior Scientist at  the Biomedical Research Center, Slovak Academy of Sciences, and Deputy Head  of Department of Tumor Biology. Her main scientific interest is focused on the role of hypoxia and acidosis in tumor development and  studying of molecular and cellular mechanisms of tumor microenvironment and cell adaptation to hypoxia and acidosis. She is interested in molecular and functional characterization of hypoxia inducible protein carbonic anhydrase IX (CA IX). She is a team leader and an independent researcher with extensive experience in the field of molecular biology, tumor biology, biochemical methods, formation of 3D models of spheroids. She is an expert in working with clinical samples, including immunohistochemical labelling, protein isolation and RNA isolation from tumor tissues.

She graduated from Comenius University, Faculty of Natural Sciences with a degree in Biochemistry (2001). In

2005 she obtained the PhD  degree at the Faculty of Natural Sciences, Comenius University Bratislava.

She worked as Postdoctoral Associate at the University of Manchester, School of Pharmacy and Pharmaceutical Sciences, United Kingdom (2006-2008). She worked also at the Faculty of Agronomy, Gembloux, Belgium (2003) and University of Tampere, Finland (2003).

She is a coinventor on patent „MN/CA9 splice variants“ WO 2008/069864.

EXECUTIVES

Júlia Brížeková
Júlia Brížeková
Office Manager
Peter Mášik
Peter Mášik
Marketing & Project Manager

Peter Mášik coordinates all research projects and the pre-clinical stages of drug development process in MABPRO. He collaborates with scientists and management and supervises the daily operations and activities of the projects such as project scheduling and project budget.

LEGAL DEPARTMENT

JUDr. Viliam Janáč, PhD.
JUDr. Viliam Janáč, PhD.
Head of Legal Department

Viliam Janáč is a head of the corporate legal department and is responsible for the legal affairs of MABPRO corporation. This role includes providing legal counsel to the Board of Directors and CEO as well. He is responible for proper maintaining of corporate interactions with EMA and the relevant state governmental bodies. He is also tasked with the implementation of key legal processes that relate to legal drafting, negotiations, and commercial agreements, including the IP rights and its legal protection.